For example, identifying activating epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer patients enables clinicians to select EGFR inhibitors for those most likely to respond, thereby improving outcomes while minimizing unnecessary toxicity [3,4]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.